DBV Technologies stock among the strongest gainers on the SBF 120 despite a monthly decline of 12.5%
DBV Technologies ranks among the strongest gainers on a downward-trending SBF 120 this Friday, posting one of the rare positive performances in the broad index. The Châtillon biotech is consolidating a rebound started the previous day, in a global market context marked by major central banks' decisions.
A modest gain that does not mask an underlying deteriorating trend over three months
DBV Technologies advances 1.26% during the session to €2.25, while the SBF 120 drops 0.77% at the same time. This movement follows the sharp rebound of the previous day, which had pushed the stock to the second place in the index. Over one month, the loss nevertheless remains at 12.45%, and over three months, the decline reaches 22.73%, which testifies to structural selling pressure still present since the summer.
The stock gains nearly 40% over one year, a gap that illustrates the pronounced volatility of the file, with monthly volatility around 20%. In terms of bearish positions, according to consulted declarations, three funds cumulatively hold 3.70% of the capital sold short, against 2.82% thirty days ago, a rise of 0.88 points in one month. This level, above the 3% threshold, indicates a significant institutional presence positioned bearishly: while one cannot deduce the precise reason, this reflects a persistence of skepticism from certain market participants on the stock, to be monitored over time.
DBV below its three moving averages, RSI close to neutrality ahead of expected FDA submission
Despite the ongoing rebound, DBV Technologies trades below its three moving averages: the 20-MA at €2.33, the 50-MA at €2.43 and the 200-MA at €3.13, representing a gap of more than 28% below the latter. The price stands in the intermediate zone between the support at €2.07 and the resistance at €2.57, without a notable breach of a technical threshold at this start of session. The RSI at 43 remains in neutral territory, without signals of buying exhaustion or oversold conditions.
On the fundamental side, during the publication of H1 2026 results on July 16, the company had indicated it anticipated submission of its BLA file to the FDA in the third quarter of 2026, with sufficient cash to sustain operations until the third quarter of 2027. This regulatory deadline remains the central reference point for monitoring the stock's evolution in the coming weeks.
